2018 Primary biliary cirrhosis Drug Development- Pipeline Analysis Report

May 2018 | | ID: 24535D65213EN
VPAResearch

Abstracts

Primary biliary cirrhosis (PBC) is a long term chronic and autoimmune disease in which the bile ducts are inflamed and gradually destroyed. This results in built of bile in the liver, resulting in damage to the liver. The rare disease has limited treatment options with FDA approving obeticholic acid plus ursodeoxycholic acid as a single therapy.

Over 25 companies and universities are focusing on developing treatment options for Primary biliary cirrhosis.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Primary biliary cirrhosis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Primary biliary cirrhosis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Primary biliary cirrhosis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 PRIMARY BILIARY CIRRHOSIS (PBC) PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Primary biliary cirrhosis (PBC) Pipeline Snapshot
2.3 Primary biliary cirrhosis (PBC) Pipeline by Phase
2.4 Primary biliary cirrhosis (PBC) Pipeline by Company
2.5 Primary biliary cirrhosis (PBC) Pipeline by Mechanism of Action

3 PRIMARY BILIARY CIRRHOSIS (PBC)- COMPANY WISE PIPELINE ANALYSIS

Albireo AB
Arena Pharmaceuticals
CymaBay Therapeutics
Enanta Pharmaceuticals
FF Pharma
Genfit
Genkyotex
GlaxoSmithKline
Intercept Pharmaceuticals
KAN Research Institute
NGM Biopharmaceuticals
Novartis
Phenex Pharmaceuticals
Retrophin
Suzhou Zelgen Biopharmaceutical Co Ltd
Tiziana Life Sciences
Virobay Inc
Zydus Cadila

4 PRIMARY BILIARY CIRRHOSIS (PBC) R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN PRIMARY BILIARY CIRRHOSIS (PBC) PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Primary biliary cirrhosis (PBC) Pipeline by Phase, H1- 2018
Figure 2: Primary biliary cirrhosis (PBC) Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Primary biliary cirrhosis (PBC) Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

Table 1: Primary biliary cirrhosis (PBC) Pipeline by Phase, H1- 2018
Table 2: Primary biliary cirrhosis (PBC) Pipeline by Companies, H1- 2018
Table 3: Primary biliary cirrhosis (PBC) Pipeline by Mechanism of Action, H1- 2018
Table 4: Albireo AB Primary biliary cirrhosis Pipeline, May 2018
Table 5: Arena Pharmaceuticals Primary biliary cirrhosis Pipeline, May 2018
Table 6: CymaBay Therapeutics Primary biliary cirrhosis Pipeline, May 2018
Table 7: Enanta Pharmaceuticals Primary biliary cirrhosis Pipeline, May 2018
Table 8: FF Pharma Primary biliary cirrhosis Pipeline, May 2018
Table 9: Genfit Primary biliary cirrhosis Pipeline, May 2018
Table 10: Genkyotex Primary biliary cirrhosis Pipeline, May 2018
Table 11: GlaxoSmithKline Primary biliary cirrhosis Pipeline, May 2018
Table 12: Intercept Pharmaceuticals Primary biliary cirrhosis Pipeline, May 2018
Table 13: KAN Research Institute Primary biliary cirrhosis Pipeline, May 2018
Table 14: NGM Biopharmaceuticals Primary biliary cirrhosis Pipeline, May 2018
Table 15: Novartis Primary biliary cirrhosis Pipeline, May 2018
Table 16: Phenex Pharmaceuticals Primary biliary cirrhosis Pipeline, May 2018
Table 17: Retrophin Primary biliary cirrhosis Pipeline, May 2018
Table 18: Suzhou Zelgen Biopharmaceutical Co Ltd Primary biliary cirrhosis Pipeline, May 2018
Table 19: Tiziana Life Sciences Primary biliary cirrhosis Pipeline, May 2018
Table 20: Virobay Inc Primary biliary cirrhosis Pipeline, May 2018
Table 21: Zydus Cadila Primary biliary cirrhosis Pipeline, May 2018